StockData
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. (CTMX) stock

CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$1.94−0.05 (-2.27%)

Close on Nov 17, 2026Market cap $422.73MP/E –Yield –

CytomX Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

CytomX Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $18.30M, down 87.0% year over year. For fiscal 2025 it was $76.20M, down 44.8% from the year before. Over ten years it grew 25.7% a year on average. The highest annual figure on record is $138.10M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$76.20M-44.8%
FY2024Dec 31, 2024$138.10M+36.4%
FY2023Dec 31, 2023$101.21M+90.4%
FY2022Dec 31, 2022$53.16M+42.5%
FY2021Dec 31, 2021$37.31M-45.5%
FY2020Dec 31, 2020$68.43M+154.4%
FY2019Dec 31, 2019$26.90M-54.8%
FY2018Dec 31, 2018$59.50M-16.9%
FY2017Dec 31, 2017$71.62M+376.1%
FY2016Dec 31, 2016$15.04M+95.1%
FY2015Dec 31, 2015$7.71M+51.9%
FY2014Dec 31, 2014$5.08M+471.7%
FY2013Dec 31, 2013$888.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.42M-92.4%
Q1 FY2026Mar 31, 2026$10.26M-79.9%
Q4 FY2025Dec 31, 2025$663.00K-98.3%
Q3 FY2025Sep 30, 2025$5.96M-82.2%
Q2 FY2025Jun 30, 2025$18.66M-25.7%
Q1 FY2025Mar 31, 2025$50.92M+22.8%
Q4 FY2024Dec 31, 2024$38.09M+43.2%
Q3 FY2024Sep 30, 2024$33.43M+26.7%
Q2 FY2024Jun 30, 2024$25.12M+1.6%
Q1 FY2024Mar 31, 2024$41.46M+76.4%
Q4 FY2023Dec 31, 2023$26.61M+32.2%
Q3 FY2023Sep 30, 2023$26.38M+136.7%
Q2 FY2023Jun 30, 2023$24.72M+92.4%
Q1 FY2023Mar 31, 2023$23.50M+159.9%
Q4 FY2022Dec 31, 2022$20.12M+80.8%
Q3 FY2022Sep 30, 2022$11.15M+21.3%
Q2 FY2022Jun 30, 2022$12.85M+46.1%
Q1 FY2022Mar 31, 2022$9.04M+10.3%
Q4 FY2021Dec 31, 2021$11.13M+57.3%
Q3 FY2021Sep 30, 2021$9.19M+23.1%
Q2 FY2021Jun 30, 2021$8.80M+25.9%
Q1 FY2021Mar 31, 2021$8.20M-82.5%
Q4 FY2020Dec 31, 2020$7.08M-14.5%
Q3 FY2020Sep 30, 2020$7.47M-30.3%
Q2 FY2020Jun 30, 2020$6.99M-22.5%
Q1 FY2020Mar 31, 2020$46.90M+59.0%
Q4 FY2019Dec 31, 2019$8.28M-27.8%
Q3 FY2019Sep 30, 2019$10.71M-14.4%
Q2 FY2019Jun 30, 2019$9.01M-57.8%
Q1 FY2019Mar 31, 2019$29.49M+107.9%
Q4 FY2018Dec 31, 2018$11.47M-57.6%
Q3 FY2018Sep 30, 2018$12.51M-48.2%
Q2 FY2018Jun 30, 2018$21.34M+143.8%
Q1 FY2018Mar 31, 2018$14.18M+21.7%
Q4 FY2017Dec 31, 2017$27.07M+331.7%
Q3 FY2017Sep 30, 2017$24.14M+599.0%
Q2 FY2017Jun 30, 2017$8.75M–
Q1 FY2017Mar 31, 2017$11.65M–
Q4 FY2016Dec 31, 2016$6.27M–
Q3 FY2016Sep 30, 2016$3.45M–

More CytomX Therapeutics figures

See a number that looks wrong?